A combination of genetic and pharmacological approaches using mouse leukemia models show that STAT5 phosphorylation is one of the major drivers of the proliferation of Philadelphia chromosome–positive (BCR-ABL-positive or Ph+) chronic myeloid leukemia. Once BCR-ABL expression has been established, JAK2 is required only for lymphoid cell transformation, not for the maintenance of the lymphoid or myeloid leukemia.
This is a preview of subscription content, log in via an institution to check access.
Katie Vicari
References
Melo, J.V. & Barnes, D.J. Nat. Rev. Cancer 7, 441–453 (2007).
Clark, S.S. et al. Science 235, 85–88 (1987).
Quintas-Cardáma, A., Kantarjian, H. & Cortes, J. Nat. Rev. Drug Discov. 6, 834–848 (2007).
Druker, B.J. et al. N. Engl. J. Med. 355, 2408–2417 (2006).
Padmanabhan, S. et al. Future Oncol. 4, 359–377 (2008).
Fabbro, D., et al. Biochim. Biophys. Acta. 1804, 454–462 (2010).
O'Hare, T. et al. Cancer Cell 16, 401–412 (2009).
Carlesso, N., Frank, D.A. & Griffin, J.D. J. Exp. Med. 183, 811–820 (1996).
Sillaber, C. et al. Blood 95, 2118–2125 (2000).
Hantschel, O. et al. Nat. Chem. Biol. 8, 285–293 (2012).
Melnick, J.S. et al. Proc. Natl. Acad. Sci. USA 103, 3153–3158 (2006).
Warsch, W. et al. Blood 117, 3409–3420 (2011).
Nelson, E.A. et al. Blood 117, 3421–3429 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Fabbro, D. A new STATus in CML. Nat Chem Biol 8, 228–229 (2012). https://doi.org/10.1038/nchembio.900
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.900
- Springer Nature America, Inc.
This article is cited by
-
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
Journal of Hematology & Oncology (2014)